Amerikanische Gesellschaft für Hirudotherapie

Comprehensive Transcriptome Sequencing Analysis of Hirudinaria manillensis in Different Growth Periods

Basic science published in Front Physiol (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomik & ProteomikShan H et al. · Frontiers in physiology, 2022

Abstract

Medical leeches are widely been used in biochemical and clinical medical studies, helping to restore blood circulation to grafted or severely injured tissue. Mostly, adult leeches are being used in the traditional pharmacopeia, but the gene expression profiling of leeches in different growth periods is not well-reported. So, in this study, we used transcriptome analysis to analyze the comparative gene expression patterns of Hirudinaria manillensis (H. manillensis) in different growth periods, including larval, young, and adult stages. We constructed 24 cDNA libraries from H. manillensis larval, young, and adult stages, and about 54,639,118 sequences were generated, 18,106 mRNA transcripts of which 958 novel mRNAs and 491 lncRNAs were also assembled as well. Furthermore, the results of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed that the differentially upregulated genes from the larval to adult stages were enriched in pathways such as cilium, myofibril, contractile fiber, cytoskeleton proteins, dilated cardiomyopathy, adrenergic signaling in cardiomyocytes, etc. Moreover, in the adult stages, a significant increase in the expression of the Hirudin-HM (HIRM2) genes was detected. In addition, our comparative transcriptome profiling data from different growth stages of H. manillensis also identified a large number of DEGs and DElncRNAs which were tentatively found to be associated with the growth of H. manillensis; as it grew, the muscle-related gene expression increased, while the lipid metabolism and need for stimulation and nutrition-related genes decreased. Similarly, the higher expression of HIRM2 might attribute to the high expression of protein disulfide isomerase gene family (PDI) family genes in adulthood, which provides an important clue that why adult leeches rather than young leeches are widely used in clinical therapeutics and traditional Chinese medicine.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

RNA-Seq of Hirudinaria manillensis larval, young, and adult leeches reveals hirudin-HM upregulation in adult stage explaining clinical preference for mature leeches.

Warum dies für die Hirudotherapie relevant ist

This study performed comparative transcriptome sequencing (24 cDNA libraries) of Hirudinaria manillensis across larval, young, and adult stages, assembling ~18,106 mRNA transcripts and identifying differentially expressed genes enriched in muscle/contractile and signaling pathways, with significantly higher adult-stage expression of Hirudin-HM (HIRM2) and protein disulfide isomerase family genes, potentially explaining why adult leeches are preferred for clinical use. For ASH, this is relevant because it links developmental gene expression—particularly of hirudin-related anticoagulant transcripts—to the life stage used in hirudotherapy and traditional medicine. The caveat is that this is a descriptive transcriptomic study with no functional validation of the DEGs in vivo, no secretome protein measurement, and no clinical data, so the inferred rationale for preferring adults remains a correlation.

Zitation

Comprehensive Transcriptome Sequencing Analysis of Hirudinaria manillensis in Different Growth Periods.

Shan H et al. · Frontiers in physiology, 2022

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.